http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Anti-fibrotic Drug Discovery is ideal for postgraduate students and researchers with an interest in anti-fibrotic drug discovery as well as clinicians specialising in liver, kidney, heart and lung disease, in which fibrosis plays a key role in pathology.
TGF€ Signalling in Fibrosis; Targeting Integrins in Fibroproliferative Disease; Discovery, Structural Refinement and Therapeutic Potential of Farnesoid X Receptor (FXR) Activators; Autotaxin Inhibitors in Fibrosis; Inhibition of LOXL2 and Other Lysyl Oxidase (Like) Enzymes: Intervention at the Core of Fibrotic Pathology; Galectin-3 Involvement in Fibrotic Diseases; The Emerging Role of CXCR4 in IPF; BH3 Mimetic Drugs for Anti-Fibrotic Therapy; Intratumoral Fibrosis: Emerging Concepts and Therapeutic Opportunities; Targeting Fibroblasts in Cancer and Fibrosis
edited by Jehrod Brenneman, KSQ Therapeutics, USA and Malliga R. Iyer, National Institutes of Health, USA.
Includes bibliographical references and index.